Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jane Apperley

Showing results (101-110 of 117) with videos related to

Pageof 12
Sort By:
American Journal of Hematology|October 20, 2022
Allogeneic hematopoietic cell transplantation in patients with chronic phase chronic myeloid leukemia in the era of third generation tyrosine kinase inhibitors: A retrospective study by the chronic malignancies working party of the EBMTYves Chalandon, Giulia Sbianchi, Luuk Gras, et al.
Blood|August 24, 2013
Preclinical and clinical efficacy of XPO1/CRM1 inhibition by the karyopherin inhibitor KPT-330 in Ph+ leukemiasChristopher J Walker, Joshua J Oaks, Ramasamy Santhanam, et al.
Bone Marrow Transplantation|May 15, 2023
Are syngeneic donors a viable donor option in allogeneic haematopoietic cell transplantation for MDS? A brief report on behalf of the Chronic Malignancies Working Party of the EBMT and review of current literatureMarie Robin, Luuk Gras, Linda Koster, et al.
Bone Marrow Transplantation|March 27, 2020
Reducing the diversity of allogeneic transplant protocols in the UK through a BSBMT Anthony Nolan Protocol Harmonization InitiativeChloe Anthias, Jane Apperley, Adrian Bloor, et al.
Clinical Lymphoma, Myeloma & Leukemia|June 23, 2021
IgD Subtype But Not IgM or Non-Secretory Is a Prognostic Marker for Poor Survival Following Autologous Hematopoietic Cell Transplantation in Multiple Myeloma. Results From the EBMT CALM (Collaboration to Collect Autologous Transplant Outcomes in Lymphomas and Myeloma) StudySarah Lawless, Giulia Sbianchi, Curly Morris, et al.
Blood|August 9, 2013
Antagonistic activities of the immunomodulator and PP2A-activating drug FTY720 (Fingolimod, Gilenya) in Jak2-driven hematologic malignanciesJoshua J Oaks, Ramasamy Santhanam, Christopher J Walker, et al.
Bone Marrow Transplantation|April 10, 2026
Management of tyrosine kinase inhibitors and donor lymphocyte infusions post transplantation for chronic myeloid leukemia: a survey of contemporary practice on behalf of the chronic malignancies working party of the EBMTAlexandros Kanellopoulos, Linda Koster, Hugues de Lavallade, et al.
British Journal of Haematology|April 5, 2024
Mismatched related donor allogeneic haematopoietic cell transplantation compared to other donor types for Ph+ chronic myeloid leukaemia: A retrospective analysis from the Chronic Malignancies Working Party of the EBMTFrancesco Onida, Luuk Gras, Junran Ge, et al.
Leukemia|June 3, 2021
COVID-19 and stem cell transplantation; results from an EBMT and GETH multicenter prospective surveyPer Ljungman, Rafael de la Camara, Malgorzata Mikulska, et al.
Blood|December 15, 2016
Sickle cell disease: an international survey of results of HLA-identical sibling hematopoietic stem cell transplantationEliane Gluckman, Barbara Cappelli, Francoise Bernaudin, et al.
Pageof 12

Showing results (101-110 of 117) with videos related to

Sort By:
Pageof 12
American Journal of Hematology|October 20, 2022
Allogeneic hematopoietic cell transplantation in patients with chronic phase chronic myeloid leukemia in the era of third generation tyrosine kinase inhibitors: A retrospective study by the chronic malignancies working party of the EBMTYves Chalandon, Giulia Sbianchi, Luuk Gras, et al.
Blood|August 24, 2013
Preclinical and clinical efficacy of XPO1/CRM1 inhibition by the karyopherin inhibitor KPT-330 in Ph+ leukemiasChristopher J Walker, Joshua J Oaks, Ramasamy Santhanam, et al.
Bone Marrow Transplantation|May 15, 2023
Are syngeneic donors a viable donor option in allogeneic haematopoietic cell transplantation for MDS? A brief report on behalf of the Chronic Malignancies Working Party of the EBMT and review of current literatureMarie Robin, Luuk Gras, Linda Koster, et al.
Bone Marrow Transplantation|March 27, 2020
Reducing the diversity of allogeneic transplant protocols in the UK through a BSBMT Anthony Nolan Protocol Harmonization InitiativeChloe Anthias, Jane Apperley, Adrian Bloor, et al.
Clinical Lymphoma, Myeloma & Leukemia|June 23, 2021
IgD Subtype But Not IgM or Non-Secretory Is a Prognostic Marker for Poor Survival Following Autologous Hematopoietic Cell Transplantation in Multiple Myeloma. Results From the EBMT CALM (Collaboration to Collect Autologous Transplant Outcomes in Lymphomas and Myeloma) StudySarah Lawless, Giulia Sbianchi, Curly Morris, et al.
Blood|August 9, 2013
Antagonistic activities of the immunomodulator and PP2A-activating drug FTY720 (Fingolimod, Gilenya) in Jak2-driven hematologic malignanciesJoshua J Oaks, Ramasamy Santhanam, Christopher J Walker, et al.
Bone Marrow Transplantation|April 10, 2026
Management of tyrosine kinase inhibitors and donor lymphocyte infusions post transplantation for chronic myeloid leukemia: a survey of contemporary practice on behalf of the chronic malignancies working party of the EBMTAlexandros Kanellopoulos, Linda Koster, Hugues de Lavallade, et al.
British Journal of Haematology|April 5, 2024
Mismatched related donor allogeneic haematopoietic cell transplantation compared to other donor types for Ph+ chronic myeloid leukaemia: A retrospective analysis from the Chronic Malignancies Working Party of the EBMTFrancesco Onida, Luuk Gras, Junran Ge, et al.
Leukemia|June 3, 2021
COVID-19 and stem cell transplantation; results from an EBMT and GETH multicenter prospective surveyPer Ljungman, Rafael de la Camara, Malgorzata Mikulska, et al.
Blood|December 15, 2016
Sickle cell disease: an international survey of results of HLA-identical sibling hematopoietic stem cell transplantationEliane Gluckman, Barbara Cappelli, Francoise Bernaudin, et al.
Pageof 12